Wells Fargo
NGNE icon

Wells Fargo’s Neurogene NGNE Stock Holding History

Wells Fargo’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$86K Sell
4,268
-6,769
-61% -$131K ﹤0.01% 5184
2025
Q4 		$227K Buy
11,037
+3,438
+45% +$85.6K ﹤0.01% 5000
2025
Q3 		$132K Buy
7,599
+1,232
+19% +$24.7K ﹤0.01% 5171
2025
Q2 		$95.2K Sell
6,367
-53
-0.8% -$832 ﹤0.01% 5221
2025
Q1 		$75.2K Buy
6,420
+976
+18% +$17K ﹤0.01% 5240
2024
Q4 		$124K Buy
5,444
+1,397
+35% +$52K ﹤0.01% 5075
2024
Q3 		$170K Buy
4,047
+30
+0.7% +$1.16K ﹤0.01% 4686
2024
Q2 		$146K Buy
4,017
+3,546
+753% +$125K ﹤0.01% 4711
2024
Q1 		$24K Buy
471
+57
+14% +$1.9K ﹤0.01% 5531
2023
Q4 		$8.02K Buy
414
+1
+0.2% +$14 ﹤0.01% 5885
2023
Q3 		$6.53K Buy
413
+1
+0.2% +$15 ﹤0.01% 5908
2023
Q2 		$6.84K Hold
412
– – ﹤0.01% 6012
2023
Q1 		$5.76K Buy
412
+1
+0.2% +$12 ﹤0.01% 6017
2022
Q4 		$4.19K Hold
411
– – ﹤0.01% 5824
2022
Q3 		$5K Hold
411
– – ﹤0.01% 5911
2022
Q2 		$8K Sell
411
-162
-28% -$3.95K ﹤0.01% 5844
2022
Q1 		$22K Sell
573
-661
-54% -$38.6K ﹤0.01% 5978
2021
Q4 		$118K Buy
1,234
+755
+158% +$92K ﹤0.01% 5546
2021
Q3 		$69K Sell
479
-120
-20% -$18.4K ﹤0.01% 5520
2021
Q2 		$110K Sell
599
-146
-20% -$32.3K ﹤0.01% 5271
2021
Q1 		$184K Sell
745
-1,798
-71% -$460K ﹤0.01% 5194
2020
Q4 		$717K Buy
2,543
+85
+3% +$20.8K ﹤0.01% 4265
2020
Q3 		$591K Sell
2,458
-359
-13% -$87K ﹤0.01% 4227
2020
Q2 		$936K Buy
2,817
+2,805
+23,375% +$731K ﹤0.01% 3864
2020
Q1 		$3K Buy
+12
New +$2.47K ﹤0.01% 5944
2018
Q2 		– Sell
-184
Closed -$52K – 6484
2018
Q1 		$52K Buy
+184
New +$50.8K ﹤0.01% 5554
2016
Q4 		– Sell
-38
Closed -$10K – 6380
2016
Q3 		$10K Buy
+38
New +$7.66K ﹤0.01% 5763

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Wells Fargo's NGNE Position: Q1 2026 in Review

Wells Fargo reduced its Neurogene (NGNE) stake by 61% in Q1 2026, selling an estimated $131K and leaving 4,268 shares worth $86K. The position accounts for ﹤0.01% of the portfolio, ranked #5184.

Wells Fargo first reported a position in NGNE in Q3 2016 and has held it in 27 quarters since. The position peaked at $936K in Q2 2020. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Wells Fargo held 4,268 shares of Neurogene worth $86K as of Q1 2026.
  • Wells Fargo sold 6,769 Neurogene shares in Q1 2026, an estimated $131K.
  • Neurogene made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5184 holding.
  • Wells Fargo first reported a position in Neurogene in Q3 2016 and has held it in 27 quarters since.
  • Wells Fargo's Neurogene position peaked at $936K in Q2 2020.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.